U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07450820) titled 'OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD' on Feb. 04.
Brief Summary: This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD)
Study Start Date: Feb. 18
Study Type: OBSERVATIONAL
Condition:
Chronic Kidney Disease
Recruitment Status: RECR...